

**Advanced Enzyme Technologies Ltd.**

CIN: L24200MH1989PLC051018

Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India

Tel: +91-22-4170 3200, Fax: +91-22-2583 5159

Email: info@advancedenzymes.com, www.advancedenzymes.com

January 31, 2026

**BSE Limited**

P. J. Towers,  
Dalal Street,  
Mumbai- 400 001

**Scrip Code-540025**

**Subject: Press Release**

**Ref: ISIN: INE837H01020**

**National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1,  
G Block, Bandra-Kurla Complex,  
Bandra (E) Mumbai- 400 051

**Trading Symbol-ADVENZYMES**

**Dear Sir/Madam,**

Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is Press Release, titled "Quarterly Earnings Release" dated January 31, 2026.

This is for your information and for public at large.

Thanking you,

Yours faithfully,

**For Advanced Enzyme Technologies Limited**

**Sanjay Basantani**

**Company Secretary and Head – Legal**

Encl.: As above

FOR IMMEDIATE RELEASE

## QUARTERLY EARNINGS RELEASE

Thane, India: Saturday, January 31, 2026

### Advanced Enzyme Technologies Limited announces Financial Results for Third Quarter and Nine Months ended December 2025

Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, with global leadership in the manufacturing of enzymes, today announced their unaudited financial results for third quarter and nine months ended December 2025.

#### CONSOLIDATED QUARTERLY FINANCIAL HIGHLIGHTS:

(Amount in INR Mn.)	Q3 FY26	Q2 FY26	Q3 FY25	Change (Y-o-Y %)	Change (Q-o-Q %)	9M FY26	9M FY25	Change (%)
Revenue	1,719	1,845	1,691	+2%	-7%	5,424	4,697	+15%
EBITDA	494	601	553	-11%	-18%	1,658	1,488	+11%
EBITDA Margin (%)	29%	33%	33%			31%	32%	
PAT	432	447	389	+11%	-3%	1,284	1,072	+20%
PAT Margin (%)	25%	24%	23%			24%	23%	
EPS	3.80	3.87	3.36	+13%	-2%	11.24	9.36	+20%

#### CONSOLIDATED FINANCIAL REVIEW (Y-o-Y basis):

##### Revenue from Operations:

Revenue from operations on consolidated basis increased to ₹ 1,719 million in the Q3 FY26 from ₹ 1,691 million in the Q3 FY25, a growth of 2%.

##### Profit:

Consolidated EBITDA during Q3 FY26 stands at ₹ 494 million as compared to ₹ 553 million during Q3 FY25, decrease of 11%.

Profit before tax stands at ₹ 583 million during Q3 FY26 as against ₹ 530 million in Q3 FY25, an increase of 10%.

Profit after tax grew by 11% and stands at ₹ 432 million during Q3 FY26 as compared to ₹ 389 million during the Q3 FY25.

##### Margin:

EBITDA margin stands at 29%, PBT margin stands at 34% and PAT margin stands at 25% during the quarter.

##### Financial Costs:

Financial costs stood at ₹ 6 million during Q3 FY26 as against ₹ 9 million in Q3 FY25.

##### Depreciation and Amortization:

Depreciation and Amortization charge for the Q3 FY26 stood at ₹ 102 million as compared to ₹ 90 million in the same quarter previous year.

##### Earnings Per Share:

Earnings Per Share during Q3 FY26 stands at ₹ 3.80 as compared to ₹ 3.36 in Q3 FY25.

## OPERATIONAL PERFORMANCE REVIEW:


### Segmental Revenue:

(Amount in INR Mn.)	Q3 FY26	Q3 FY25	Change (%)
Human Nutrition	962	1,018	-6%
Animal Nutrition	241	197	+22%
Bio-Processing	361	321	+13%
Specialized Manufacturing	155	154	+0%

The total revenue from operations grew by 2% on y-o-y basis and declined by 7% on q-o-q basis.

Revenue from the Human Nutrition segment decreased by 6%, reaching ₹962 million in Q3 FY26, compared to ₹1,018 million in Q3 FY25. This impact is because of decline in the Pharma/API and Nutrition businesses across both domestic and international markets.


The Animal nutrition delivered a strong growth of 22% to ₹241 million in Q3 FY26 as against ₹197 million in Q3 FY25.



The Bio-Processing segment recorded growth of 13% during the quarter, reaching ₹361 million in Q3 FY26, compared to ₹321 million in Q3 FY25. This growth was primarily driven by the Food business, which surged 16% y-o-y to ₹310 million in Q3 FY26. In contrast, the Non-Food business declined by 5%, standing at ₹51 million for the quarter.

The Specialized Manufacturing segment contributed 9% to the total revenue, amounting to ₹155 million during the quarter.

### Geographical Revenue:



Domestic sales accounted for ₹ 801 million in Q3 FY26 as compared to ₹759 million in Q3 FY25, higher by 6%.

The total revenue includes international sales of ₹919 million in Q3 FY26, compared to ₹932 million in Q3 FY25, representing a y-o-y decrease of 1%. The revenue declined by 11% in the Americas and 9% in Europe. Asia (ex-India) recorded growth of 14% and the rest of the world reported robust growth of 40%.

During Q3 FY26, domestic sales accounted for 47% compared with 45% in Q3 FY25, while international sales accounted for 53% of revenue from operations compared with 55% in Q3 FY25.

## CONSOLIDATED FINANCIAL REVIEW (Q-o-Q basis):

### Revenue from Operations:

Revenue from operations on consolidated basis decreased to ₹ 1,719 million in the Q3 FY26 from ₹ 1,845 million in the Q2 FY26, a de-growth of 7%.

### Profit:

Consolidated EBITDA during Q3 FY26 stands at ₹ 494 million as compared to ₹ 601 million during Q2 FY26, lower by 18%.

Profit before tax stands at ₹ 583 million during Q3 FY26 as against ₹ 595 million in Q2 FY26, an decrease of 2%

Profit after tax de-grew by 3% and stands at ₹ 432 million during Q3 FY26 as compared to

₹ 447 million during the Q2 FY26.

### Financial Costs:

Financial costs stood at ₹ 6 million during Q3 FY26 as against ₹ 7 million in Q2 FY26.

### Depreciation and Amortization:

Depreciation and Amortization charge for the Q3 FY26 is ₹ 102 million as compared to ₹ 101 million in the last quarter.

### Earnings Per Share:

Earnings Per Share during Q3 FY26 stands at ₹ 3.80 as compared to ₹ 3.87 in Q2 FY26.

## OPERATIONAL PERFORMANCE REVIEW:

### Segmental Revenue:

(Amount in INR Mn.)	Q3 FY26	Q2 FY26	Change (%)
Human Nutrition	962	1,212	-21%
Animal Nutrition	241	193	+25%
Bio-Processing	361	255	+41%
Specialized Manufacturing	155	185	-16%

The human nutrition segment de-grew by 21% to ₹ 962 million in Q3 FY26 as compared to ₹ 1,212 million in Q2 FY26.

The animal nutrition business recorded growth of 25%, reaching ₹241 million in Q3 FY26, as compared to ₹193 million in Q2 FY26.

The Bio-Processing segment recorded an 41% sequential growth, generating ₹361 million in Q3 FY26 compared to ₹255 million in Q2 FY26. Within this segment, the Food business grew by 51% to ₹310 million and the Non-Food business by 3% to ₹51 million, compared to the previous quarter.

The Specialized Manufacturing segment delivered a de-growth of 16%, reaching ₹155 million in Q3 FY26, up from ₹185 million in Q2 FY26.

### Geographical Revenue:

Domestic Sales amounted to ₹801 million in Q3 FY26, compared to ₹887 million in Q2 FY26, reflecting a sequential decline of 10%. Domestic sales accounted for approximately 47% of total revenue from operations, compared to 48% in Q2 FY26.

International Sales marginally declined by 4% to ₹919 million in Q3 FY26, down from ₹958 million

in Q2 FY26. The revenue de-grew by 10% in Americas, 17% in Europe and 13% in Asia (ex-India), while the rest of the world recorded a strong growth of 214%. International sales now represent 53% of total revenue from operations, up from 52% in Q2 FY26.

## CONSOLIDATED NINE MONTHS (YTD) FINANCIAL REVIEW (Y-o-Y basis):

### Revenue from Operations:

Revenue from operations on consolidated basis increased to ₹ 5,424 million in the 9M FY26 from ₹ 4,697 million in the 9M FY25, reported higher by 15%.

### Profit:

Consolidated EBITDA during 9M FY26 stands at ₹ 1,658 million as compared to ₹ 1,488 million during 9M FY25, growth of 11%.

Profit before tax stands at ₹ 1,727 million during 9M FY26 as against ₹ 1,439 million in 9M FY25, an increase of 20%.

Profit after tax stands at ₹ 1,284 million during 9M FY26 as compared to ₹ 1,072 million during the 9M FY25, an increase of 20%.

### Margin:

EBITDA margin stands at 31%, PBT margin stands at 32% and PAT margin stands at 24% during the 9M FY26.

### Financial Costs:

Financial costs stood at ₹ 21 million during 9M FY26 as against ₹ 27 million in 9M FY25.

### Depreciation and Amortization:

Depreciation and Amortization charge for the 9M FY26 is ₹ 299 million as compared to ₹ 265 million in 9M FY25.

### Earnings Per Share:

Earnings Per Share during 9M FY26 stands at ₹ 11.24 as compared to ₹ 9.36 in 9M FY25.

## OPERATIONAL PERFORMANCE REVIEW:


### Segmental Revenue:

(Amount in INR Mn.)	9M FY26	9M FY25	Change (%)
Human Nutrition	3,396	3,022	+12%
Animal Nutrition	694	551	+26%
Bio-Processing	852	740	+15%
Specialized Manufacturing	482	385	+25%

The Human Nutrition segment reported 12% growth, reaching ₹ 3,396 million in 9M FY26, compared to ₹ 3,022 million in 9M FY25.

The Animal Nutrition segment also demonstrated robust growth, increasing by 26% to ₹ 694 million in 9M FY26, up from ₹ 551 million in 9M FY25.


The Bio-Processing segment grew by 15% during the nine month, contributing ₹ 852 million in 9M FY26, compared to ₹ 740 million in 9M FY25. Within this segment, the Food business



accounted for 13% of total revenue, reaching ₹ 691 million, delivering 19% growth, while the Non-Food business contributed 3%, amounting to ₹ 161 million, with 1% growth.

The Specialized Manufacturing segment contributed 9% to the total revenue, growing by 25% YTD, reaching ₹ 482 million in 9M FY26.

### Geographical Revenue:



International Sales contributed ₹2,758 million in 9M FY26, compared to ₹2,496 million in 9M FY25,

reflecting growth of 10% y-o-y. The revenue declined by 6% in the Americas, while registering robust growth of 30% in Europe, 60% in Asia (ex-India), and 35% in the rest of the world

Domestic Sales amounted to ₹2,666 million in 9M FY26, compared to ₹2,201 million in 9M FY25, representing a 21% y-o-y increase. Domestic sales contributed approximately 49% of total revenue from operations, up from 47% in 9M FY25, while international sales accounted for the remaining 51%, slightly lower than 53% in 9M FY25.

## OUTLOOK 2025-26

Advanced Enzymes remains committed to enhancing and strengthening its business model by maintaining a strong focus across its three key segments—Human Nutrition, Animal Nutrition, and Bio-Processing. The company is actively working on expanding its product portfolio, particularly in the probiotics space, through ongoing development and new product launches. With its current infrastructure and capital investments, Advanced Enzymes is well-positioned to grow its enzymes and probiotics business.

### **Human Nutrition:**

The Company already operates a successful B2C business in the USA and is now replicating this model in India to drive growth and explore new opportunities. It remains committed to expanding its B2C presence within the Human Nutrition sector. As part of this strategy, the Company has launched its own nutraceutical brand, Wellfa, targeting to Indian consumers. The brand offers a wide range of products, including immune support, skincare, gut health, metabolism enhancement, detox solutions, weight management, stress relief, and respiratory health, among others.

This segment is expected to become a key growth driver for the Company. Additionally, it is selling through other online platforms to diversify and strengthen its digital sales channels.

### **Animal Nutrition:**

In the Animal Nutrition segment, the Company is actively carrying out trials and research to develop innovative and more effective nutritional products aimed at enhancing the performance of animal feeds. Efforts are underway to register and launch additional products in both domestic and international markets. Simultaneously, the Company plans to expand its sales and marketing teams across the USA, MENA, and Asian regions, while also aiming to broaden its global presence by appointing new distributors in international markets.

### **Probiotics:**

The Company continuously make efforts on introducing additional probiotic products in the Human Nutrition segment, focusing on immunity enhancement, active health foods, gut health, and various nutraceutical applications. In the Animal

Nutrition segment, it is committed to launching new products aimed at boosting immunity, improving digestion, and enhancing the nutritional value of animal feed.

### **Bio Catalysis:**

The Company has achieved notable progress in developing biocatalysis for API manufacturers, offering targeted enzymatic solutions that help reduce energy consumption, processing time, and chemical usage. Some of these products are at various stages of development, with a few currently in advanced plant-level trials with API manufacturers. This area represents a key opportunity where the Company intends to maintain its focus and ongoing efforts.

### **Baking:**

The Company offers a diverse portfolio of enzymes for the food processing sector and has submitted 15 dossiers to the European Food Safety Authority (EFSA), receiving positive opinions for 9 of them. Its product range demonstrates efficacy and performance on par with leading industry players. With a strong focus on value-driven solutions, the Company is well-positioned to expand its presence across Europe, the Americas, and other global markets, particularly within the baking industry.

### **Research & Development:**

The Company is making substantial investments in state-of-the-art R&D infrastructure, aiming to lead innovation in the formulation of new applications. With a strong focus on expanding its application portfolio across various industries, the Company remains committed to ongoing R&D investment. It also plans to further strengthen its R&D team to support this growth and drive future advancements.

### **Inorganic expansion:**

The Company has a strong track record of inorganic growth, having successfully completed four acquisitions over the past nine years, all financed through internal accruals, maintaining its status as a zero-debt entity. It will continue to explore strategic acquisition opportunities that can enhance its front-end marketing capabilities, expand its geographical footprint, strengthen its product portfolio, and bolster its B2C business.

## RESULTS CONFERENCE CALL DETAILS

Advanced Enzymes will hold an earnings conference call on 4<sup>th</sup> February 2026, Wednesday at 16:00 Hours IST to discuss quarterly performance. The transcript of the call will be available later in the Investor Relations section on the Company's website, [www.advancedenzymes.com](http://www.advancedenzymes.com)

Please dial the numbers at least 5-10 minutes prior to the conference schedule to ensure that you are connected on time.

Conference Call Primary Number: + 91 86 3416 8799 / +91 86 4536 6917

**Pre-registration link**

### For further information, please contact:

#### **Ronak Saraf**

Investor Relations

 ir@advancedenzymes.com

### **CORPORATE INFORMATION:**

Advanced Enzyme Technologies Limited  
Regd. Office: 5<sup>th</sup> Floor, 'A' Wing, Sun Magnetica,  
Louiswadi, Thane (W) -400 604,  
Maharashtra, India  
Tel.: +91 22 41703200  
Fax: +91-22 25835159  
Website: [www.advancedenzymes.com](http://www.advancedenzymes.com)  
CIN No: L24200MH1989PLC051018